SEC Company Response from SEELOS THERAPEUTICS, INC. (SEEL) (CIK 0001017491) — Feb 3, 2020
SEELOS THERAPEUTICS, INC. (SEEL) (CIK 0001017491)
Date: Feb. 3, 2020 · CIK: 0001017491 · Accession: 0001136261-20-000031
AI Filing Summary & Sentiment
File numbers found in text: 333-236002
Letter
_
Seelos Therapeutics, Inc.
300 Park Avenue, 12th Floor
New York, NY 10022
February 3, 2020
VIA EDGAR
Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549-0406
Re: Seelos Therapeutics, Inc.
Registration Statement on Form S-1, Initially Filed on January 22, 2020, as amended
File No. 333-236002
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Seelos Therapeutics, Inc. (the "Company") hereby respectfully requests that the effectiveness of the Registration Statement on Form S-1 (Registration No. 333-236002) of the Company, filed with the Securities and Exchange Commission on January 22, 2020, as amended (the "Registration Statement"), be accelerated so that such Registration Statement shall become effective at 5:00 p.m. (Eastern Time) on February 5, 2020, or as soon as possible thereafter.
The Company hereby confirms that it is aware of its responsibilities under the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, as they relate to the proposed offering of the securities specified in the Registration Statement.
It would be appreciated if, promptly after the Registration Statement has become effective, you would so inform our outside counsel, Jeffrey T. Hartlin of Paul Hastings LLP, by telephone at (650) 320-1804 or by email at jeffhartlin@paulhastings.com. The Company hereby authorizes Mr. Hartlin or Ms. Samantha H. Eldredge of Paul Hastings LLP to orally modify or withdraw this request for acceleration.
Sincerely,
SEELOS THERAPEUTICS, INC.
Show Raw Text
CORRESP
1
filename1.htm
_
Seelos Therapeutics, Inc.
300 Park Avenue, 12th Floor
New York, NY 10022
February 3, 2020
VIA EDGAR
Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549-0406
Re: Seelos Therapeutics, Inc.
Registration Statement on Form S-1, Initially Filed on January 22, 2020, as amended
File No. 333-236002
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Seelos Therapeutics, Inc. (the "Company") hereby
respectfully requests that the effectiveness of the Registration Statement on Form S-1 (Registration No. 333-236002) of the Company, filed with the Securities and Exchange Commission on
January 22, 2020, as amended (the "Registration Statement"), be accelerated so that such Registration Statement shall become effective at 5:00 p.m. (Eastern Time) on
February 5, 2020, or as soon as possible thereafter.
The Company hereby confirms that it is aware of its responsibilities under the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, as
they relate to the proposed offering of the securities specified in the Registration Statement.
It would be appreciated if, promptly after the Registration Statement has become effective, you would so inform our outside counsel, Jeffrey T. Hartlin of Paul Hastings LLP,
by telephone at (650) 320-1804 or by email at jeffhartlin@paulhastings.com. The Company hereby authorizes Mr. Hartlin or Ms. Samantha H. Eldredge of Paul Hastings LLP to orally modify or
withdraw this request for acceleration.
Sincerely,
SEELOS THERAPEUTICS, INC.
By:
/s/ Raj Mehra, Ph.D.
Raj Mehra, Ph.D.
President and Chief Executive Officer
cc:
Jeffrey T. Hartlin, Esq. (Paul Hastings LLP)